Teriparatide Reconstitution Calculator

Yes. Teriparatide is recombinant human parathyroid hormone (PTH) 1–34. It is approved for osteoporosis in postmenopausal women and men at high fracture risk, and for glucocorticoid-induced osteoporosis. (RCT) In a pivotal trial, 20 µg/day subcutaneously reduced vertebral fractures by 65% and appendicular fractures by 35% over 18 months; lumbar spine bone mineral density increased 9.7% and total hip 2.6%.

The standard osteoporosis dose is 20 µg once daily by subcutaneous injection; no body-weight adjustment is used in adults (community protocol). Pharmacokinetics show rapid absorption (Tmax ~30 min), elimination half-life ~1 h, and total exposure ~4 h; serum calcium peaks about 4.25 h after dosing and returns to baseline by 16–24 h. For refractory postoperative hypocalcemia with hungry bone features, a case report used 20 µg twice daily, later reduced to once daily. For delayed long-bone union, a prospective study used 20 µg daily for 3 months.

The osteoporosis course is typically 18–24 months, with a cumulative lifetime limit (practitioner consensus/regulatory guidance) based on long-term rat toxicology data showing osteosarcoma at high doses; no human clinical-trial osteosarcoma was reported among approximately 2,800 treated patients. Anabolic effects decline after 6–12 months. Teriparatide must be followed by an antiresorptive to preserve bone mass; only 25% of patients receive timely consolidation within 3 months in US data (observational cohort).

In pregnancy- and lactation-associated osteoporosis, teriparatide, abaloparatide, or romosozumab are preferred options with concurrent contraception; bisphosphonates cross the placenta. (observational/position statement) In children with hypoparathyroidism, a meta-analysis of 94 pediatric patients found teriparatide maintained serum calcium and lowered phosphate, but conventional calcium/active vitamin D remains first-line.

Partially. A meta-analysis found prior bisphosphonate exposure was associated with a smaller lumbar spine BMD increase (−2.21%) versus bisphosphonate-naive patients, but no significant attenuation at the hip or femoral neck; adjusted fracture outcomes did not show clear attenuation. Older data similarly show alendronate can blunt the anabolic response.

Real-world propensity-matched data found romosozumab initiation was associated with lower risks of any osteoporotic fracture and spine/hip fracture than teriparatide. (observational) In glucocorticoid-induced osteoporosis, a network meta-analysis found teriparatide produced greater lumbar spine BMD gains than alendronate, risedronate, denosumab, and zoledronate, but was not significantly different from romosozumab.

Evidence is strongest for spinal fusion and nonunion. A meta-analysis of spinal fusion surgery found perioperative teriparatide was associated with lower proximal junctional kyphosis (RR 0.40) and radiographic nonunion (RR 0.66 per patient). (meta-analysis) In delayed long-bone union, 81.2% achieved radiologic union at 12 weeks with 20 µg/day. For medication-related osteonecrosis of the jaw, adjunctive teriparatide improved staging and healing time (pooled HR 5.35).

FAERS pharmacovigilance identified teriparatide as one of the most frequently reported drugs among hypercalcemia reports, with 2,539 cases. (observational) After injection, serum calcium rises transiently but persistent hypercalcemia is rare. Nausea, headache, dizziness, and leg cramps occur; hypercalcemia required dose reduction in 3% and discontinuation in 0.2% in the pivotal trial.